Document Detail

The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.
MedLine Citation:
PMID:  9007858     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Recurrent malignant meningiomas and unresectable meningiomas represent a great therapeutic challenge after the failure of radiation therapy. No effective chemotherapy has been found. We report the preliminary results of the treatment of patients with recurrent unresectable or malignant meningiomas with recombinant interferon alpha-2B (IFN-alpha-2B). METHOD: Each of six patients with either a recurrent malignant meningioma or an unresectable meningioma was treated with IFN-alpha, administered subcutaneously at a dosage of 4 mU/m2 per day, 5 days per week. Two of the six meningiomas were regular, one was atypical, and three were malignant. RESULTS: Five of six patients exhibited positive response to treatment; with stabilization of the size of the tumor in four patients and slight regression in one. The responses observed lasted from 6 to 14 months. The toxicity associated with prolonged use of IFN-alpha was mild and well tolerated. CONCLUSION: These results suggest that IFN-alpha is effective in the treatment of recurrent malignant meningiomas.
S E Kaba; F DeMonte; J M Bruner; A P Kyritsis; K A Jaeckle; V Levin; W K Yung
Related Documents :
21275468 - Combination of capecitabine and mitomycin c as first-line treatment in patients with me...
7946588 - Low-dose gamma-interferon therapy is ineffective in renal cell carcinoma patients with ...
8381188 - Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase ii tr...
21540018 - Update on the management of high-risk squamous cell carcinoma.
17609188 - Environmental uncertainty, autocorrelation and the evolution of survival.
21346038 - Treatment-associated adverse event management in the advanced renal cell carcinoma pati...
Publication Detail:
Type:  Case Reports; Clinical Trial; Clinical Trial, Phase II; Journal Article    
Journal Detail:
Title:  Neurosurgery     Volume:  40     ISSN:  0148-396X     ISO Abbreviation:  Neurosurgery     Publication Date:  1997 Feb 
Date Detail:
Created Date:  1997-04-10     Completed Date:  1997-04-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7802914     Medline TA:  Neurosurgery     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  271-5     Citation Subset:  IM    
Department of Neuro-Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Brain / pathology
Dose-Response Relationship, Drug
Drug Administration Schedule
Injections, Subcutaneous
Interferon Alfa-2b / administration & dosage*,  adverse effects
Magnetic Resonance Imaging
Meningeal Neoplasms / pathology,  therapy*
Meningioma / pathology,  therapy*
Middle Aged
Neoplasm Recurrence, Local / pathology,  therapy*
Neoplasm Staging
Treatment Outcome
Reg. No./Substance:
99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cystic craniopharyngioma: long-term results after intracavitary irradiation with stereotactically ap...
Next Document:  The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study usin...